Stockscreener 앱 받기
46.65
4.07%
-1.98
시간 외 거래:
46.70
0.05
+0.11%
Bristol Myers Squibb Co 주식(BMY)의 최신 뉴스
Is Bristol Myers Squibb Company stock a safe investment in uncertain markets2025 Support & Resistance & Intraday High Probability Setup Alerts - newser.com
Good Life Advisors LLC Decreases Position in Bristol Myers Squibb Company $BMY - MarketBeat
Is Bristol Myers Squibb Company (BRM) stock a contrarian opportunityMarket Trend Review & Safe Capital Preservation Plans - newser.com
Boston Partners Sells 3,760,655 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Scotiabank Initiates Coverage on Bristol Myers (BMY) with Sector Perform Rating and $45 Target - Finviz
Is Bristol Myers Squibb Company Celegne Contingent stock resilient in recession scenarios2025 Price Momentum & Long-Term Safe Return Strategies - newser.com
Police & Firemen s Retirement System of New Jersey Increases Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Banco Bilbao Vizcaya Argentaria S.A. Purchases 15,599 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Shares Sold by Arvest Bank Trust Division - MarketBeat
Allianz SE Lowers Position in Bristol Myers Squibb Company $BMY - MarketBeat
Blood thinner failure thins BMS shares - The Pharma Letter
Bristol Myers, J&J halt heart drug trial after interim review - ETPharma.com
Tech Rebounds After Selloff, Bitcoin Craters To $97,000: What's Moving Markets Friday? - Benzinga
Scotiabank Initiates Coverage on Bristol Myers Squibb (NYSE:BMY) - MarketBeat
Bristol Myers, J&J’s new blood thinner fails first big test - BioPharma Dive
Bristol Myers, J&J stop blood clotting drug trial after interim review - Reuters
Bristol Myers Faces Another Trial Disappointment As Heart Drug Milvexian Fails To Show Efficacy - Benzinga
Wealth Alliance LLC Cuts Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Vestmark Advisory Solutions Inc. Trims Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb shares slide after halting key heart trial - MSN
Bristol-Myers Squibb stock falls after discontinuing acute coronary trial By Investing.com - Investing.com Canada
Next-generation blood thinner from Bristol Myers Squibb, J&J fails key trial - statnews.com
Bristol Myers (BMY) Drops Following Phase 3 Trial Halt - GuruFocus
Bristol Myers falls after halting heart drug trial - TradingView
Bristol Myers Squibb discontinues Librexia ACS trial after review By Investing.com - Investing.com Canada
Bristol Myers Squibb Company $BMY Shares Sold by Nwam LLC - MarketBeat
Cherokee Insurance Co Takes $1.42 Million Position in Bristol Myers Squibb Company $BMY - MarketBeat
Update on phase 3 Librexia ACS trial - MarketScreener
Candriam S.C.A. Sells 92,461 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Forsta AP Fonden Has $19.34 Million Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Q&A: BioNTech co-founders discuss bispecific efforts, Bristol Myers deal, and the irony of competing with Pfizer - Endpoints News
Wealth Quarterback LLC Raises Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Shares Purchased by KBC Group NV - MarketBeat
ProShare Advisors LLC Acquires 37,125 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
About us - Bristol Myers Squibb
Bristol-Myers Squibb’s Oncology Strategy Gains Momentum - AD HOC NEWS
SCRI, BMS Expand Collaboration to Accelerate Patient Enrollment - Contract Pharma
Bristol Myers Squibb, Sarah Cannon expand oncology trial partnership - Investing.com
Does Bristol-Myers Squibb’s Rebound Signal Opportunity After Recent Biotech Acquisitions? - Yahoo Finance
Bristol Myers (NYSE: BMY) and SCRI broaden cancer trial access via Accelero at 200+ sites - Stock Titan
Zions Bancorporation National Association UT Trims Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Evotec and BMS partnership yields IND approval - BioWorld MedTech
Evotec Receives $5 Million Milestone Payment From Bristol Myers Under Protein Degradation Partnership - MarketScreener
Bristol Myers Squibb Company $BMY Stake Boosted by denkapparat Operations GmbH - MarketBeat
Privacy notice center - Bristol Myers Squibb
Evotec Receives Milestone Payment from Bristol Myers Squibb Following IND Acceptance in Strategic Protein Degradation Partnership - ACCESS Newswire
Published on: 2025-11-12 00:59:26 - newser.com
Evotec gets USD 5 mln milestone payment from Bristol Myers Squibb - MarketScreener
Evotec receives milestone payment from Bristol Myers Squibb following IND acceptance in strategic protein degradation partnership - TradingView
Bernstein Assigns Bristol-Myers Squibb Company (BMY) a Hold Rating - Insider Monkey
Jim Cramer on Bristol-Myers: “I’m Backing off on It” - Insider Monkey
Bristol Myers Squibb Co. Stock Rises Monday, Still Underperforms Market - 富途牛牛
Illinois Municipal Retirement Fund Sells 74,227 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Daiwa Securities Adjusts Price Target on Bristol-Myers Squibb to $43 From $42, Maintains Neutral Rating - MarketScreener
Bristol Myers Squibb Company $BMY Shares Bought by King Luther Capital Management Corp - MarketBeat
Midwest Trust Co Invests $5.67 Million in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb (BMY): Assessing Valuation After Improved Profits and Upgraded Revenue Guidance - Yahoo Finance
Prospera Financial Services Inc Sells 10,360 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Campbell & CO Investment Adviser LLC Purchases Shares of 42,998 Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Shares Sold by CENTRAL TRUST Co - MarketBeat
BofA Remains Neutral on Bristol-Myers Squibb Company (BMY), Expects Low Single-Digit Growth in the Long Term - Insider Monkey
Bristol-Myers Squibb (BMY) Completes Significant Debt Offering - GuruFocus
0.38%
0.22%
자본화:
|
볼륨(24시간):